◎ Sugi Atlas

Atlas / Drug / Lenvatinib

Lenvatinib

drug
On this page

Also known as E-7080KisplyxSID137276042E7080 (LENVATINIB)

Summary

Lenvatinib (CHEMBL1289601) is an approved small-molecule vascular endothelial growth factor receptor antagonist (ATC L01EX08) targeting KDR and FLT4; indicated across 62 conditions including neoplasm and non-small cell lung carcinoma; with CIViC clinical evidence for 3 variant-indication associations (e.g. EGFR Amplification OR EGFR Alteration in hepatocellular carcinoma).

At a glance

  • Status: Approved (max clinical phase 4)
  • Modality: Small molecule
  • ATC class: L01EX08
  • Targets: 2 (KDR, FLT4)
  • Indications: 62 conditions
  • Clinical trials: 440
  • Precision-oncology evidence (CIViC): 3 variant–indication associations
  • Chemistry: 426.9 Da · C21H19ClN4O4

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL1289601
NameLenvatinib
TypeSmall molecule
Max phase4
FDA approvedyes
PubChem CID9823820
ChEBICHEBI:85994
ATCL01EX08
Molecular formulaC21H19ClN4O4
Molecular weight426.9
InChIKeyWOSKHXYHFSIKNG-UHFFFAOYSA-N

SMILES: COC1=CC2=NC=CC(=C2C=C1C(=O)N)OC3=CC(=C(C=C3)NC(=O)NC4CC4)Cl

IUPAC name: 4-[3-chloro-4-(cyclopropylcarbamoylamino)phenoxy]-7-methoxyquinoline-6-carboxamide

ChEBI definition: A member of the class of quinolines that is the carboxamide of 4-{3-chloro-4-[(cyclopropylcarbamoyl)amino]phenoxy}-7-methoxyquinoline-6-carboxylic acid. A multi-kinase inhibitor and orphan drug used (as its mesylate salt) for the treatment of various types of thyroid cancer that do not respond to radioiodine.

Pharmacological roles (ChEBI): vascular endothelial growth factor receptor antagonist, orphan drug, antineoplastic agent, EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor, fibroblast growth factor receptor antagonist.

Also known as: E-7080, Kisplyx, Lenvatinib, LENVATINIB, SID137276042, lenvatinib, E7080 (LENVATINIB), E7080 (Lenvatinib)

Parent form; salt/anhydrous children: CHEMBL2105704, CHEMBL3527309

Patent coverage: 3,746 distinct patent families (8,784 SureChEMBL compound mentions), from 3 matched compound structure(s). One matched structure accounts for 7,986 (91%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

GeneTargetActionpAffinityCancer dependencyUniProt
KDRkinase insert domain receptorInhibition8.41.1%P35968
FLT4fms related receptor tyrosine kinase 4Inhibition8.280.2%P35916

Broader ChEMBL bioactivity targets: 40 (assay-derived). Sample: Serine/threonine-protein kinase/endoribonuclease IRE1, Mitogen-activated protein kinase kinase kinase 6, Receptor-interacting serine/threonine-protein kinase 3, Tyrosine-protein kinase ABL1, Vascular endothelial growth factor receptor 1, Platelet-derived growth factor receptor beta, Mast/stem cell growth factor receptor Kit, Vascular endothelial growth factor receptor 3, Platelet-derived growth factor receptor alpha, Proto-oncogene tyrosine-protein kinase receptor Ret.

Bioactivity

ChEMBL activities: 66 potent at pChembl ≥ 5 of 69 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

TargetpChemblTypeValueUnitActivity ID
KDR9.15IC500.7nMCHEMBL_ACT_19225818
RET8.82Ki1.5nMCHEMBL_ACT_15247904
RET8.82Ki1.5nMCHEMBL_ACT_25935696
RET8.82IC501.5nMCHEMBL_ACT_29235666
FGFR48.72IC501.9nMCHEMBL_ACT_25567329
FLT18.7IC502nMCHEMBL_ACT_29153331
KDR8.7IC502nMCHEMBL_ACT_29153332
FLT48.7IC502nMCHEMBL_ACT_29153333
KDR8.68Kd2.1nMCHEMBL_ACT_14982871
KDR8.57IC502.7nMCHEMBL_ACT_29065563
KDR8.52AC503nMCHEMBL_ACT_25168092
FLT18.47IC503.4nMCHEMBL_ACT_29065526
KDR8.4IC504nMCHEMBL_ACT_12138555
KDR8.4IC504nMCHEMBL_ACT_18149408
KDR8.4IC504nMCHEMBL_ACT_18854166
KDR8.4IC504nMCHEMBL_ACT_22809993
KDR8.4IC504nMCHEMBL_ACT_23289714
KDR8.4IC504nMCHEMBL_ACT_26001072
KDR8.4IC504nMCHEMBL_ACT_3595759
FLT48.28IC505.2nMCHEMBL_ACT_12138554
FLT48.28IC505.2nMCHEMBL_ACT_18854176
FLT48.28IC505.2nMCHEMBL_ACT_22809995
FLT48.28IC505.2nMCHEMBL_ACT_23289722
RET8.22IC506nMCHEMBL_ACT_29153339
RET8.05Kd9nMCHEMBL_ACT_17935120
RET8IC5010nMCHEMBL_ACT_15247907
RET8IC5010nMCHEMBL_ACT_15247908
RET8IC5010nMCHEMBL_ACT_15247909
RIPK27.96Kd11nMCHEMBL_ACT_17935350
FGFR27.96IC5011nMCHEMBL_ACT_25567316

Target pathways

Aggregated over 2 target gene(s): KDR, FLT4.

Top Reactome pathways

8 total, by targets touching each:

PathwayTargetsGenes
VEGF binds to VEGFR leading to receptor dimerization2FLT4, KDR
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells2FLT4, KDR
Neuropilin interactions with VEGF and VEGFR1KDR
Integrin cell surface interactions1KDR
VEGFA-VEGFR2 Pathway1KDR
VEGFR2 mediated cell proliferation1KDR
NOTCH4 Intracellular Domain Regulates Transcription1FLT4
Signaling by membrane-tethered fusions of PDGFRA or PDGFRB1KDR

Dominant GO biological processes

GO termTargets
angiogenesis2
positive regulation of protein phosphorylation2
positive regulation of endothelial cell proliferation2
lymph vessel development2
cell surface receptor protein tyrosine kinase signaling pathway2
positive regulation of cell population proliferation2
positive regulation of endothelial cell migration2
cell migration2
peptidyl-tyrosine phosphorylation2
positive regulation of cell migration2
cellular response to vascular endothelial growth factor stimulus2
vascular endothelial growth factor signaling pathway2
positive regulation of MAPK cascade2
protein autophosphorylation2
vascular endothelial growth factor receptor signaling pathway2

Indications & clinical

Indications

62 indications (2 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

IndicationTrial phaseMONDOEFO
neoplasm4MONDO:0005070EFO:0000616
non-small cell lung carcinoma3MONDO:0005233EFO:0003060
renal cell carcinoma3MONDO:0005086EFO:0000681
hepatocellular carcinoma3MONDO:0007256EFO:0000182
melanoma3MONDO:0005105EFO:0000756
endometrium neoplasm3MONDO:0021251EFO:0004230
thyroid gland papillary carcinoma3MONDO:0005075EFO:0000641
urothelial carcinoma3MONDO:0040679EFO:0008528
intrahepatic cholangiocarcinoma3MONDO:0003210EFO:1001961
head and neck squamous cell carcinoma3MONDO:0010150EFO:0000181
cholangiocarcinoma3MONDO:0019087EFO:0005221
colorectal neoplasm3MONDO:0005335EFO:0004142
esophageal squamous cell carcinoma3MONDO:0005580EFO:0005922
clear cell renal carcinoma3MONDO:0005005EFO:0000349
endometrial carcinoma3MONDO:0002447EFO:1001512
renal carcinoma3MONDO:0005206EFO:0002890
thyroid gland carcinoma3MONDO:0015075EFO:0002892
renal cell adenocarcinoma3MONDO:0005549EFO:0005708
adenoid cystic carcinoma2MONDO:0004971EFO:0000231
thyroid gland follicular carcinoma2MONDO:0005034EFO:0000501
lung adenocarcinoma2MONDO:0005061EFO:0000571
mesothelioma2MONDO:0005065EFO:0000588
osteosarcoma2MONDO:0009807EFO:0000637
neuroendocrine neoplasm2MONDO:0019496EFO:1001901
gastric neoplasm2MONDO:0021085MONDO:0001056
breast neoplasm2MONDO:0021100MONDO:0007254
ovarian cancer2MONDO:0008170MONDO:0008170
adenocarcinoma2MONDO:0004970EFO:0000228
sarcoma2MONDO:0005089EFO:0000691
neuroendocrine carcinoma2MONDO:0002120MONDO:0002120
small cell lung carcinoma2MONDO:0008433EFO:0000702
cutaneous neuroendocrine carcinoma2MONDO:0019210EFO:1001471
gastric carcinoma2MONDO:0004950EFO:0000178
biliary tract neoplasm2MONDO:0005304EFO:0003891
uterine carcinosarcoma2MONDO:0006485EFO:1000613
adrenal cortex carcinoma2MONDO:0006639EFO:1000796
kidney cancer2MONDO:0002367MONDO:0002367
gastric adenocarcinoma2MONDO:0005036EFO:0000503
Kaposi’s sarcoma2MONDO:0005055EFO:0000558
cervical carcinoma2MONDO:0005131EFO:0001061
thymic carcinoma2MONDO:0006451EFO:1000576
vulva cancer2MONDO:0001528MONDO:0001528
malignant pleural mesothelioma2MONDO:0005112EFO:0000770
ovarian carcinoma2MONDO:0005140EFO:0001075
paraganglioma2MONDO:0000448EFO:1000453
liver disorder1MONDO:0005154EFO:0001421
lymphoma1MONDO:0005062EFO:0000574
rectal cancer1MONDO:0006519EFO:1000657
kidney disorder1MONDO:0005240EFO:0003086
central nervous system neoplasm1MONDO:0006130EFO:1000158
glioblastoma1MONDO:0018177EFO:0000519
pancreatic ductal adenocarcinoma1MONDO:0005184MONDO:0005184

10 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 440.

Phase distribution

PhaseTrials
PHASE2229
PHASE350
Not specified50
PHASE1/PHASE247
PHASE140
PHASE49
PHASE2/PHASE38
EARLY_PHASE17

Top trials by phase / activity

NCTPhaseStatusTitle
NCT06311916PHASE4NOT_YET_RECRUITINGEfficacy and Safety of Neoadjuvant Therapy in Patients With Resectable HCC Screened by a Multimodal Deep Learning Model.
NCT06311929PHASE4RECRUITINGPrecision Adjuvant Therapy After Surgery for Hepatocellular Carcinoma
NCT06417606PHASE4NOT_YET_RECRUITINGLenvatinib and Adebrelimab Combined With GEMOX in the Perioperative Treatment of Potentially Resectable Intrahepatic Cholangiocarcinoma
NCT07010393PHASE4NOT_YET_RECRUITINGGenotype-Driven Neoadjuvant Therapy for Locally Advanced Thyroid Cancer: A Real-World Cohort Study
NCT07160361PHASE4NOT_YET_RECRUITINGExploration of Postoperative Adjuvant Therapy for HCC Patients With Positive TB
NCT03573960PHASE4COMPLETEDA Study to Evaluate the Safety and Efficacy of Lenvatinib in Participants With Refractory Differentiated Thyroid Cancer
NCT04127396PHASE4UNKNOWNLenvatinib Plus TACE Versus Sorafenib Plus TACE for HCC With PVTT
NCT04297254PHASE4COMPLETEDA Study to Assess the Safety and Efficacy of Lenvatinib as First-line Treatment in Participants With Unresectable HCC
NCT05949424PHASE4UNKNOWNOPTI - DOSE: Optimal Dosing of Oral Anticancer Drugs in Older Adults
NCT02811861PHASE3ACTIVE_NOT_RECRUITINGLenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma
NCT03486873PHASE3RECRUITINGLong-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
NCT04039607PHASE3ACTIVE_NOT_RECRUITINGA Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma
NCT04164199PHASE3ACTIVE_NOT_RECRUITINGStudy of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies
NCT04586231PHASE3ACTIVE_NOT_RECRUITINGA Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)
NCT04736706PHASE3ACTIVE_NOT_RECRUITINGA Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)
NCT04770896PHASE3ACTIVE_NOT_RECRUITINGA Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab
NCT04949256PHASE3ACTIVE_NOT_RECRUITINGEfficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014)
NCT05077215PHASE3NOT_YET_RECRUITINGEfficacy and Safety of a Repurposed Drug Added to the Combination of Len Plus Pem in Advanced Endometrial Cancer
NCT05301842PHASE3ACTIVE_NOT_RECRUITINGEvaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC
NCT05408221PHASE2/PHASE3RECRUITINGthe Efficacy and Safety of Rulonilimab in Combination With Lenvatinib in Hepatocellular Carcinoma
NCT05608200PHASE3RECRUITINGLenvatinib+Sintilimab+TACE vs. Lenvatinib+TACE for Advanced HCC
NCT05608213PHASE3RECRUITINGLenvatinib Plus I-125 Seed Brachytherapy vs. Lenvatinib for TACE-refractory HCC
NCT05718232PHASE3NOT_YET_RECRUITINGSBRT Plus Lenvatinib and TACE for Advanced Primary HCC: A Phase 3 Trial (SEARCH)
NCT05899049PHASE3ACTIVE_NOT_RECRUITINGA Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, vs Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)-China Extension Study
NCT06041477PHASE3RECRUITINGConcurrently vs Sequentially Combined HAIC With Targeted and Immunotherapy in Potentially Resectable HCC
NCT06089382PHASE3NOT_YET_RECRUITINGA Study to Evaluate Sintilimab Plus Lenvatinib as Adjuvant Therapy in Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis (PVTT) After Surgical Resection
NCT06201065PHASE3RECRUITINGFOLFOX-HAIC Plus Lenvatinib and Toripalimab vs. FOLFOX-HAIC Plus Lenvatinib for Advanced Hepatocellular Carcinoma: a Randomized Controlled and Double-blind Trial
NCT06364631PHASE3RECRUITINGCARE1 Pragmatic Clinical Trial
NCT06371157PHASE3RECRUITINGA Study of AK104+Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma
NCT07177716PHASE2/PHASE3NOT_YET_RECRUITINGEfficacy and Safety of LB1410 Plus Lenvatinib With or Without LB4330 in Advanced Recurrent/Metastatic Cervical Cancer
NCT07383441PHASE3NOT_YET_RECRUITINGAdding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer
NCT07405164PHASE3RECRUITINGExtension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)
NCT07475026PHASE3NOT_YET_RECRUITINGA Study of Neoadjuvant Tislelizumab Plus Lenvatinib in Resectable HCC at High Risk of Recurrence
NCT07537946PHASE3NOT_YET_RECRUITINGLocal Consolidation After Sintilimab Plus Lenvatinib for Metastatic Liver Cancer
NCT01321554PHASE3COMPLETEDA Multicenter, Randomized, Double-Blind, Placebo-Controlled, Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer (DTC)
NCT01761266PHASE3COMPLETEDA Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-line Treatment of Participants With Unresectable Hepatocellular Carcinoma
NCT02966093PHASE3COMPLETEDA Trial of Lenvatinib (E7080) in Radioiodine (131 I)-Refractory Differentiated Thyroid Cancer in China
NCT03517449PHASE3COMPLETEDLenvatinib in Combination With Pembrolizumab Versus Treatment of Physician’s Choice in Participants With Advanced Endometrial Cancer (MK-3475-775/E7080-G000-309 Per Merck Standard Convention [KEYNOTE-775])
NCT03713593PHASE3COMPLETEDSafety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002/E7080-G000-311/LEAP-002)
NCT03744247PHASE3WITHDRAWNLenvatinib Plus PD-1 Antibody Versus Lenvtinib Alone for Advanced HCC

Clinical evidence (CIViC)

Variant × indication × effect (3 predictive associations from 3 curated evidence items):

VariantIndicationEffectTherapyLevelCIViC
EGFR Amplification OR EGFR AlterationHepatocellular CarcinomaResistanceLenvatinibCIViC BEID12052
KDR R1032QColorectal CancerSensitivity/ResponseLenvatinib + Axitinib + Cabozantinib + DovitinibCIViC DEID9339
KIF5B::RET Fusion AND RET G810ALung Non-small Cell CarcinomaSensitivity/ResponsePonatinib + LenvatinibCIViC DEID4853

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline, but PharmGKB curates 0 clinical and 3 variant annotation(s) for this drug (gene-keyed; see PharmGKB).

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

171 molecules share ≥1 primary target. Top 60 by shared-target count:

MoleculeSourceStatusShared targets
CRIZOTINIBChEMBL + PubChemPhase 4 (approved)FLT4, KDR
GEFITINIBChEMBL + PubChemPhase 4 (approved)FLT4, KDR
PAZOPANIBChEMBL + PubChemPhase 4 (approved)FLT4, KDR
REGORAFENIBChEMBL + PubChemPhase 4 (approved)FLT4, KDR
AXITINIBChEMBLPhase 4 (approved)FLT4, KDR
BRIGATINIBChEMBLPhase 4 (approved)FLT4, KDR
CABOZANTINIBChEMBLPhase 4 (approved)FLT4, KDR
ENTRECTINIBChEMBLPhase 4 (approved)FLT4, KDR
ERLOTINIBChEMBLPhase 4 (approved)FLT4, KDR
FEDRATINIBChEMBLPhase 4 (approved)FLT4, KDR
FRUQUINTINIBChEMBLPhase 4 (approved)FLT4, KDR
INFIGRATINIBChEMBLPhase 4 (approved)FLT4, KDR
MIDOSTAURINChEMBLPhase 4 (approved)FLT4, KDR
NINTEDANIBChEMBLPhase 4 (approved)FLT4, KDR
NINTEDANIB ESYLATEChEMBLPhase 4 (approved)FLT4, KDR
QUIZARTINIBChEMBLPhase 4 (approved)FLT4, KDR
SORAFENIBChEMBLPhase 4 (approved)FLT4, KDR
SUNITINIBChEMBLPhase 4 (approved)FLT4, KDR
TIVOZANIBChEMBLPhase 4 (approved)FLT4, KDR
VANDETANIBChEMBLPhase 4 (approved)FLT4, KDR
BRIVANIBChEMBLPhase 3FLT4, KDR
CEDIRANIBChEMBLPhase 3FLT4, KDR
CEP-1347ChEMBLPhase 3FLT4, KDR
DOVITINIBChEMBLPhase 3FLT4, KDR
LESTAURTINIBChEMBLPhase 3FLT4, KDR
LINIFANIBChEMBLPhase 3FLT4, KDR
MOTESANIBChEMBLPhase 3FLT4, KDR
SEMAXANIBChEMBLPhase 3FLT4, KDR
SURUFATINIBChEMBLPhase 3FLT4, KDR
VATALANIBChEMBLPhase 3FLT4, KDR
AT-9283ChEMBLPhase 2FLT4, KDR
BFH-772ChEMBLPhase 2FLT4, KDR
CENISERTIBChEMBLPhase 2FLT4, KDR
DANUSERTIBChEMBLPhase 2FLT4, KDR
DEFOSBARASERTIBChEMBLPhase 2FLT4, KDR
DORAMAPIMODChEMBLPhase 2FLT4, KDR
ELLAGIC ACIDChEMBLPhase 2FLT4, KDR
FORETINIBChEMBLPhase 2FLT4, KDR
ILORASERTIBChEMBLPhase 2FLT4, KDR
LUCITANIBChEMBLPhase 2FLT4, KDR
MK-2461ChEMBLPhase 2FLT4, KDR
OSI-632ChEMBLPhase 2FLT4, KDR
R-406ChEMBLPhase 2FLT4, KDR
RAF-265ChEMBLPhase 2FLT4, KDR
REBASTINIBChEMBLPhase 2FLT4, KDR
SOTRASTAURINChEMBLPhase 2FLT4, KDR
SU-014813ChEMBLPhase 2FLT4, KDR
TAK-715ChEMBLPhase 2FLT4, KDR
TANDUTINIBChEMBLPhase 2FLT4, KDR
TELATINIBChEMBLPhase 2FLT4, KDR
TOZASERTIBChEMBLPhase 2FLT4, KDR
AfatinibPubChemApprovedFLT4, KDR
SelumetinibPubChemApprovedFLT4, KDR
GENTIAN VIOLETChEMBL + PubChemPhase 4 (approved)KDR
ABEMACICLIBChEMBLPhase 4 (approved)KDR
ABROCITINIBChEMBLPhase 4 (approved)KDR
ACALABRUTINIBChEMBLPhase 4 (approved)KDR
ALECTINIBChEMBLPhase 4 (approved)KDR
AUROTHIOGLUCOSEChEMBLPhase 4 (approved)KDR
CABOZANTINIB S-MALATEChEMBLPhase 4 (approved)KDR

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 30

This page pulls from 30 datasets indexed by BioBTree:

chebichembl_activitychembl_moleculechembl_targetcivic_evidenceclingen_dosageclinical_trialsdepmapefoensemblentrezgogoparentgtopdbgtopdb_interactiongtopdb_ligandhgncmeshmondomsigdbpatent_compoundpharmgkbpharmgkb_guidelinepubchempubchem_activityreactomereactomeparentrefseqtranscriptuniprot